CBUS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 35.8%, SMA50 66.56%, SMA200 102.9%). The stock’s 14-day RSI is 70.37 (overbought), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.37% below its high and over 222.94% above its low. Average 10-day trading volume of 560.87 thousand shares is slightly above the 3-month average of 393.41 thousand, indicating heightened recent market interest.

Cibus, Inc. generated EPS of -$3.22 over the past year. Five-year average earnings growth is 29.09%. Wall Street analysts project EPS growth of 50.54% annually over the next five years. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $3.00. The high target offers 642.57% upside. The low target suggests 48.51% downside. The mean target is $9.00. This offers 345.54% upside. Cibus, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by 22.22%. The prior quarter beat by -2.33%. Over the last six quarters, Apple has recorded several small beats. These include 27.94% in March 20, 2025.

Cibus, Inc. has 52.54 million shares outstanding. The public float is 36.42 million shares, elevated short interest at 2.84% of float. This equals 1.25 million shares. The short ratio is 6.44 days. Institutional investors hold 43.63% of the float. Insiders own 33.53%. Gocal Gregory Francis William holds 314.84 thousand shares, Sauer Noel has 105.48 thousand shares and Broos Carlo has 74.20 thousand shares.

Cibus, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.81. This means the shares are trading below this model’s fair value.

Cibus, Inc. (NASDAQ:CBUS) closed at $2.02 USD, gaining $0.12 (6.32%) from the previous close of $1.90. The stock is currently mid-range between its 52-week high and low $1.09 and $4.19. With a market capitalization of about $91.88 million, Cibus, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.65). Key stats such as the average daily volume over the past year has been around 370.76 thousand shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Cibus, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Peter Beetham, the company employs approximately 118 people and listed since July 20, 2017. Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits.

Cibus, Inc. trades at a P/E ratio of -1.14, slightly below the S&P 500 average, with a price-to-sales ratio of 21.49 and a price-to-book ratio of 37.21 reflecting a rich premium to book value. The P/FCF stands at -1.82, also above market averages. Compared to sector medians, Cibus, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Cibus, Inc. (NASDAQ:CBUS) shares are flat -2.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cibus, Inc. trading at a premium to the broader market with a P/E of -1.14. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $18.94, suggesting 837.62% upside. Our AI forecast model points to short-term weakness (-3.96% over two weeks), a medium-term fall (-18.81% over three months), and a longer-term gain (51.49% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cibus, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.96%, with price expected at $1.94 by July 23, 2026, within a range of $1.86 to $2.02 3-Month Outlook: Projected fall of -18.81%, reaching $1.64 by October 07, 2026, with a range of $1.30 to $1.77. 1-Year Outlook: Projected gain of 51.49%, with price at $3.06 by July 09, 2027, within a range of $0.97 to $2.95.